Pursuant to the regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, Ishita Drugs and Industries has informed that the Board of Directors of the company, at its meeting held today 14th November, 2022 have: Approved the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022. The company has enclosed Limited Review Report of the Unaudited Financial Results of the Company for the quarter ended 30th September, 2022 issued by the Statutory Auditors of the Company.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1654.70 |
| Dr. Reddys Lab | 1232.00 |
| Cipla | 1229.60 |
| Zydus Lifesciences | 915.45 |
| Lupin | 2332.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: